The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD).
The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by 24%, the company said, Reuters reported. With the US FDA nod, the drug, chemically known as semaglutide, became the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease. Last year, the FDA had approved the use of Wegovy for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
